Canagliflozin, an inhibitor of sodium-glucose co-transporter 2, advances in the treatment of type 2 diabetes

doi:10.5246/jcps.2022.08.049

Abstract

Abstract:

Canagliflozin (CANA) is a sodium-glucose co-transporter 2 inhibitor. One of the important mechanisms of CANA is the inhibitory effect on the glucose uptake in the proximal tubule of the nephron, and the other mechanism can be the reduction of inflammatory cytokine expression monocytes and macrophages. It is proved by FDA for the management of type 2 diabetes. In the present work, we summarized the publication and clinical evidence of the CANA on healthy individuals and those with related metabolic diseases, such as type 1 and 2 diabetes, obesity, or cardiovascular and kidney diseases. This drug has been reported to offer potential advantages in regulating body weight and reducing heart failure, hypoglycemia, and stroke risk in patients with type 2 diabetes. Some in vitro and animal experiments also show that this drug has good effects on cancer treatment. However, some case reports and experiments also show the side effect of CANA, such as amputation, fracture, and pancreatitis, while the mechanism is still unknown. Overall, CANA has a good effect on the management of type 2 diabetes by reducing the risk of kidney failure, cardiovascular diseases, and stroke. However, as a new drug, more clinical trials and experiments of CANA should be carried out in the future.

Key words: Sodium-glucose co-transporter 2 inhibitors, Canagliflozin, Diabetes mellitus

Supporting:

Ying Fu, Simo Liu, Yan Ma, Nannan Wu. Canagliflozin, an inhibitor of sodium-glucose co-transporter 2, advances in the treatment of type 2 diabetes[J]. Journal of Chinese Pharmaceutical Sciences, 2022, 31(8): 569-588.

Figures/Tables 2

References 103

[1]	Association, A.D. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018, 41, 917–928.
[2]	Maki, T.; Maeno, S.; Maeda, Y.; Yamato, M.; Sonoda, N.; Ogawa, Y.; Wakisaka, M.; Inoguchi, T. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: a possible role of SGLT2 in mesangial cells. Sci. Rep. 2019, 9, 4703.
[3]	Hung, M.H.; Chen, Y.L.; Chen, L.J.; Chu, P.Y.; Hsieh, F.S.; Tsai, M.H.; Shih, C.T.; Chao, T.I.; Huang, C.Y.; Chen, K.F. Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced β-catenin activation. Cell Death Dis. 2019, 10, 420.
[4]	Behnammanesh, G.; Durante, Z.E.; Peyton, K.J.; Martinez-Lemus, L.A.; Brown, S.M.; Bender, S.B.; Durante, W. Canagliflozin inhibits human endothelial cell proliferation and tube formation. Front. Pharmacol. 2019, 10, 362.
[5]	Nasiri-Ansari, Ν.; Dimitriadis, G.K.; Agrogiannis, G.; Perrea, D.; Kostakis, I.D.; Kaltsas, G.; Papavassiliou, A.G.; Randeva, H.S.; Kassi, E. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc. Diabetol. 2018, 17, 106.
[6]	Mancini, S.J.; Boyd, D.; Katwan, O.J.; Strembitska, A.; Almabrou, T. A.; Kennedy, S.; Palmer, T.M.; Salt, I.P. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and-independent mechanisms. Sci. Rep. 2018, 8, 5276.
[7]	Xu, C.; Wang, W.; Zhong, J.; Lei, F.; Xu, N.H.; Zhang, Y.O.; Xie, W.D. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem. Pharmaco. 2018, 152, 45–59.
[8]	Kabil, S.L.; Mahmoud, N.M. Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation. Eur. J. Pharmacol. 2018, 828, 135–145.
[9]	Li, H.J.; Tong, C.W.S.; Leung, Y.; Wong, M.H.; To, K.K.W.; Leung, K.S. Identification of clinically approved drugs indacaterol and canagliflozin for repurposing to treat epidermal growth factor tyrosine kinase inhibitor-resistant lung cancer. Front. Oncol. 2017, 7, 288.
[10]	Rizvi, S.M.D.; Shakil, S.; Biswas, D.; Shakil, S.; Shaikh, S.; Bagga, P.; Kamal, M.A. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease-diabetes type 2 linkage via an enzoinformatics study. CNS Neurol. Disord. Drug Targets. 2014, 13, 447–451.
[11]	Secker, P.F.; Beneke, S.; Schlichenmaier, N.; Delp, J.; Gutbier, S.; Leist, M.; Dietrich, D.R. Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect. Cell Death Dis. 2018, 9, 226.
[12]	Mamidi, R.N.V.S.; Cuyckens, F.; Chen, J.; Scheers, E.; Kalamaridis, D.; Lin, R.H.; Silva, J.; Sha, S.E.; Evans, D.C.; Kelley, M.F.; Devineni, D.; Johnson, M.D.; Lim, H.K. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. Drug Metab. Dispos. 2014, 42, 903–916.
[13]	Sarnoski-Brocavich, S.; Hilas, O. Canagliflozin (invokana), a novel oral agent for type-2 diabetes. P T. 2013, 38, 656–666.
[14]	Kaushal, S.; Singh, H.; Thangaraju, P.; Singh, J. Canagliflozin: a novel SGLT2 inhibitor for type 2 diabetes mellitus. N Am. J. Med. Sci. 2014, 6, 107–113.
[15]	Dias, B.C.L.; Fachi, M.M.; de Campos, M.L.; Degaut, F.L.D.; Peccinini, R.G.; Pontarolo, R. A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers. Biomed. Chromatogr. 2019, 33, e4663.
[16]	Hu, W.; Yang, Y.R.; Zhang, Q.; Yang, Y.; Zhou, R.P.; Lu, C.; Liu, Z.Y. Pharmacokinetics and bioequivalence of two oral formulations of canagliflozin after single-dose administration in healthy Chinese subjects. Int. J. Clin. Pharmacol. Ther. 2020, 58, 57–65.
[17]	Devineni, D.; Murphy, J.; Wang, S.S.; Stieltjes, H.; Rothenberg, P.; Scheers, E.; Mamidi, R.N.V.S. Absolute oral bioavailability and pharmacokinetics of canagliflozin: a microdose study in healthy participants. Clin. Pharmacol. Drug Dev. 2015, 4, 295–304.
[18]	Devineni, D.; Manitpisitkul, P.; Murphy, J.; Stieltjes, H.; Ariyawansa, J.; di Prospero, N.A.; Rothenberg, P. Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants. Clin. Pharmacol. Drug Dev. 2015, 4, 279–286.
[19]	Patel, N.S.; van Name, M.A.; Cengiz, E.; Carria, L.R.; Weinzimer, S.A.; Tamborlane, W.V.; Sherr, J.L. Altered patterns of early metabolic decompensation in type 1 diabetes during treatment with a SGLT2 inhibitor: an insulin pump suspension study. Diabetes Technol. Ther. 2017, 19, 618–622.
[20]	Henry, R.R.; Thakkar, P.; Tong, C.; Polidori, D.; Alba, M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015, 38, 2258–2265.
[21]	Qiu, R.; Capuano, G.; Meininger, G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J. Clin. Transl. Endocrinol. 2014, 1, 54–60.
[22]	Inagaki, N.; Harashima, S.I.; Kaku, K.; Kondo, K.; Maruyama, N.; Otsuka, M.; Kawaguchi, Y.; Iijima, H. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2018, 20, 812–820.
[23]	Kadowaki, T.; Inagaki, N.; Kondo, K.; Nishimura, K.; Kaneko, G.; Maruyama, N.; Nakanishi, N.; Iijima, H.; Watanabe, Y.; Gouda, M. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 2017, 19, 874–882.
[24]	Harashima, S.I.; Inagaki, N.; Kondo, K.; Maruyama, N.; Otsuka, M.; Kawaguchi, Y.; Watanabe, Y. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: a 52-week, open-label, phase IV study. Diabetes Obes. Metab. 2018, 20, 1770–1775.
[25]	Rosenstock, J.; Chuck, L.; González-Ortiz, M.; Merton, K.; Craig, J.; Capuano, G.; Qiu, R. Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy for drug-Naïve type 2 diabetes. Diabetes Care. 2016, 39, 353–362.
[26]	Zhou, Z.E.; Lindley, R.I.; Rådholm, K.; Jenkins, B.; Watson, J.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Shaw, W.; Oh, R.; Desai, M.; Matthews, D.R.; Neal, B. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke. 2019, 50, 396–404.
[27]	Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Desai, M.; Li, Q.; Deng, H.; Rosenthal, N.; Jardine, M.J.; Bakris, G.; Perkovic, V. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018, 138, 1537–1550.
[28]	Rådholm, K.; Figtree, G.; Perkovic, V.; Solomon, S.D.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Barrett, T.D.; Shaw, W.; Desai, M.; Matthews, D.R.; Neal, B. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018, 138, 458–468.
[29]	Mahaffey, K.W.; Neal, B.; Perkovic, V.; Zeeuw, D E.; Fulcher, G.; Erondu, N,; Shaw, W,; Fabbrini, E,; Sun, T,; Li, Q,; Desai, M,; Matthews,D.R.CANA for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (CANA Cardiovascular Assessment Study). Circulation. 2018, 137, 323–334.
[30]	Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 2017, 377, 644–657.
[31]	Pfeifer, M.; Townsend, R.R.; Davies, M.J.; Vijapurkar, U.; Ren, J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc. Diabetol. 2017, 16, 29.
[32]	Cai, J.; Delahanty, L.M.; Akapame, S.; Slee, A.; Traina, S. Impact of canagliflozin treatment on health-related quality of life among people with type 2 diabetes mellitus: a pooled analysis of patient-reported outcomes from randomized controlled trials. Patient. 2018, 11, 341–352.
[33]	Inagaki, N.; Harashima, S.I.; Maruyama, N.; Kawaguchi, Y.; Goda, M.; Iijima, H. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 2016, 15, 89.
[34]	Davies, M.J.; Merton, K.; Vijapurkar, U.; Yee, J.; Qiu, R. Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data. Cardiovasc. Diabetol. 2017, 16, 40.
[35]	Lavalle-González, F.J.; Januszewicz, A.; Davidson, J.; Tong, C.; Qiu, R.; Canovatchel, W.; Meininger, G. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013, 56, 2582–2592.
[36]	Nyirjesy, P.; Sobel, J.D.; Fung, A.; Mayer, C.; Capuano, G.; Ways, K.; Usiskin, K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr. Med. Res. Opin. 2014, 30, 1109–1119.
[37]	Sinclair, A.; Bode, B.; Harris, S.; Vijapurkar, U.; Mayer, C.; Fung, A.; Shaw, W.; Usiskin, K.; Desai, M.; Meininger, G. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr. Disord. 2014, 14, 37.
[38]	Weir, M.R.; Kline, I.; Xie, J.; Edwards, R.; Usiskin, K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr. Med. Res. Opin. 2014, 30, 1759–1768.
[39]	Usiskin, K.; Kline, I.; Fung, A.; Mayer, C.; Meininger, G. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results. Postgrad. Med. 2014, 126, 16–34.
[40]	Weir, M.R.; Januszewicz, A.; Gilbert, R.E.; Vijapurkar, U.; Kline, I.; Fung, A.; Meininger, G. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J. Clin. Hypertens. 2014, 16, 875–882.
[41]	Bailey, R.A.; Vijapurkar, U.; Meininger, G.; Rupnow, M.F.T.; Blonde, L. Diabetes-related composite quality end point attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials. Clin. Ther. 2015, 37, 1045–1054.
[42]	Cefalu, W.T.; Stenlöf, K.; Leiter, L.A.; Wilding, J.P.H.; Blonde, L.; Polidori, D.; Xie, J.; Sullivan, D.; Usiskin, K.; Canovatchel, W.; Meininger, G. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015, 58, 1183–1187.
[43]	Gavin, J.R.; Davies, M.J.; Davies, M.; Vijapurkar, U.; Alba, M.; Meininger, G. The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2015, 31, 1693–1702.
[44]	Blonde, L.; Woo, V.; Mathieu, C.; Yee, J.; Vijapurkar, U.; Canovatchel, W.; Meininger, G. Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials. Curr. Med. Res. Opin. 2015, 31, 1993–2000.
[45]	Lavalle-González, F.J.; Eliaschewitz, F.G.; Cerdas, S.; Chacon, M.D.P.; Tong, C.; Alba, M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr. Med. Res. Opin. 2016, 32, 427–439.
[46]	Watts, N.B.; Bilezikian, J.P.; Usiskin, K.; Edwards, R.; Desai, M.; Law, G.; Meininger, G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2016, 101, 157–166.
[47]	Heerspink, H.J.L.; Perco, P.; Mulder, S.; Leierer, J.; Hansen, M.K.; Heinzel, A.; Mayer, G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019, 62, 1154–1166.
[48]	Garvey, W.T.; van Gaal, L.; Leiter, L.A.; Vijapurkar, U.; List, J.; Cuddihy, R.; Ren, J.; Davies, M.J. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018, 85, 32–37.
[49]	Qiu, R.; Balis, D.; Xie, J.; Davies, M.J.; Desai, M.; Meininger, G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr. Med. Res. Opin. 2017, 33, 553–562.
[50]	Leiter, L.A.; Yoon, K.H.; Arias, P.; Langslet, G.; Xie, J.; Balis, D.A.; Millington, D.; Vercruysse, F.; Canovatchel, W.; Meininger, G. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015, 38, 355–364.
[51]	Kadowaki, T.; Inagaki, N.; Kondo, K.; Nishimura, K.; Kaneko, G.; Maruyama, N.; Nakanishi, N.; Gouda, M.; Iijima, H.; Watanabe, Y. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes. Metab. 2018, 20, 453–457.
[52]	Kadowaki, T.; Inagaki, N.; Kondo, K.; Nishimura, K.; Kaneko, G.; Maruyama, N.; Nakanishi, N.; Watanabe, Y.; Gouda, M.; Iijima, H. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes. Diabetes Obes. Metab. 2018, 20, 77–84.
[53]	Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Stein, P.; Desai, M.; Shaw, W.; Jiang, J.; Vercruysse, F.; Meininger, G.; Matthews, D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. Am. Heart J. 2013, 166, 217–223.e11.
[54]	Neal, B.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Ways, K.; Desai, M.; Shaw, W.; Capuano, G.; Alba, M.; Jiang, J.; Vercruysse, F.; Meininger, G.; Matthews, D.; Group, C.T.C. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015, 38, 403–411.
[55]	Fulcher, G.; Matthews, D.R.; Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Weiss, R.; Rosenstock, J.; Capuano, G.; Desai, M.; Shaw, W.; Vercruysse, F.; Meininger, G.; Neal, B. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015, 6, 289–302.
[56]	Yale, J.F.; Xie, J.; Sherman, S.E.; Garceau, C. Canagliflozin in conjunction with sulfonylurea maintains glycemic control and weight loss over 52 weeks: a randomized, controlled trial in patients with type 2 diabetes mellitus. Clin. Ther. 2017, 39, 2230–2242.e2.
[57]	Rosenstock, J.; Aggarwal, N.; Polidori, D.; Zhao, Y.; Arbit, D.; Usiskin, K.; Capuano, G.; Canovatchel, W.; Group, C.D.2.S. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012, 35, 1232–1238.
[58]	Nicolle, L.E.; Capuano, G.; Ways, K.; Usiskin, K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr. Med. Res. Opin. 2012, 28, 1167–1171.
[59]	Nyirjesy, P.; Zhao, Y.; Ways, K.; Usiskin, K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr. Med. Res. Opin. 2012, 28, 1173–1178.
[60]	Inagaki, N.; Kondo, K.; Yoshinari, T.; Takahashi, N.; Susuta, Y.; Kuki, H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin. Pharmacother. 2014, 15, 1501–1515.
[61]	Inagaki, N.; Kondo, K.; Yoshinari, T.; Kuki, H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J. Diabetes Investig. 2015, 6, 210–218.
[62]	Inagaki, N.; Goda, M.; Yokota, S.; Maruyama, N.; Iijima, H. Effects of baseline blood pressure and low-density lipoprotein cholesterol on safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus. Adv. Ther. 2015, 32, 1085–1103.
[63]	Cefalu, W.T.; Leiter, L.A.; Yoon, K.H.; Arias, P.; Niskanen, L.; Xie, J.; Balis, D.A.; Canovatchel, W.; Meininger, G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013, 382, 941–950.
[64]	Inagaki, N.; Harashima, S.I.; Kaku, K.; Kondo, K.; Maruyama, N.; Otsuka, M.; Kawaguchi, Y.; Iijima, H. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2018, 20, 812–820.
[65]	Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 2017, 377, 644–657.
[66]	Carbone, S.; Dixon, D.L. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc. Diabetol. 2019, 18, 64.
[67]	Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Erondu, N.; Shaw, W.; Barrett, T.D.; Weidner-Wells, M.; Deng, H.; Matthews, D.R.; Neal, B. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018, 6, 691–704.
[68]	Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Desai, M.; Li, Q.; Deng, H.; Rosenthal, N.; Jardine, M.J.; Bakris, G.; Perkovic, V. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018, 138, 1537–1550.
[69]	Neuen, B.L.; Ohkuma, T.; Neal, B.; Matthews, D.R.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Li, Q.; Jardine, M.; Oh, R.; Heerspink, H.L.; Perkovic, V. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program. J. Am. Soc. Nephrol. 2019, 30, 2229–2242.
[70]	Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl. J. Med. 2019, 380, 2295–2306.
[71]	Scheen, A J. Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes: from CANVAS to CREDENCE. Revue medicale deLiege. 2019, 10, 508–513.
[72]	Jardine, M.J.; Zhou, Z.E.; Mahaffey, K.W.; Oshima, M.; Agarwal, R.; Bakris, G.; Bajaj, H.S.; Bull, S.; Cannon, C.P.; Charytan, D.M.; de Zeeuw, D.; di Tanna, G.L.; Greene, T.; Heerspink, H.J.L.; Levin, A.; Neal, B.; Pollock, C.; Qiu, R.; Sun, T.; Wheeler, D.C.; Zhang, H.; Zinman, B.; Rosenthal, N.; Perkovic, V.; Investigators, C.S. Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: a secondary analysis of the CREDENCE randomized trial. J. Am. Soc. Nephrol. 2020, 31, 1128–1139.
[73]	Mahaffey, K.W.; Jardine, M.J.; Bompoint, S.; Cannon, C.P.; Neal, B.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Capuano, G.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Sun, T.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Rosenthal, N.; Brenner, B.M.; Perkovic, V. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019, 140, 739–750.
[74]	Arnott, C.; Li, J.W.; Cannon, C.P.; de Zeeuw, D.; Neuen, B.L.; Heerspink, H.J.L.; Charytan, D.M.; Agarwal, A.; Huffman, M.D.; Figtree, G.A.; Bakris, G.; Chang, T.I.H.; Feng, K.; Rosenthal, N.; Zinman, B.; Jardine, M.J.; Perkovic, V.; Neal, B.; Mahaffey, K.W. The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial. Diabetes Obes. Metab. 2021, 23, 1652–1659.
[75]	Yagi, S.; Hirata, Y.; Ise, T.; Kusunose, K.; Yamada, H.; Fukuda, D.; Salim, H.M.; Maimaituxun, G.; Nishio, S.; Takagawa, Y.; Hama, S.R.; Matsuura, T.; Yamaguchi, K.; Tobiume, T.; Soeki, T.; Wakatsuki, T.; Aihara, K.I.; Akaike, M.; Shimabukuro, M.; Sata, M. Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus. Diabetol. Metab. Syndr. 2017, 9, 78.
[76]	Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 2017, 377, 644–657.
[77]	Rådholm, K.; Figtree, G.; Perkovic, V.; Solomon, S.D.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Barrett, T.D.; Shaw, W.; Desai, M.; Matthews, D.R.; Neal, B. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018, 138, 458–468.
[78]	Figtree, G.A.; Rådholm, K.; Barrett, T.D.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Matthews, D.R.; Shaw, W.; Neal, B. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019, 139, 2591–2593.
[79]	Kato, E.T.; Silverman, M.G.; Mosenzon, O.; Zelniker, T.A.; Cahn, A.; Furtado, R.H.M.; Kuder, J.; Murphy, S.A.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Bonaca, M.P.; Ruff, C.T.; Desai, A.S.; Goto, S.; Johansson, P.A.; Gause-Nilsson, I.; Johanson, P.; Langkilde, A.M.; Raz, I.; Sabatine, M.S.; Wiviott, S.D. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019, 139, 2528–2536.
[80]	Li, I.; Jardine, M.J.; Neal, B.; Heerspink, H.L.; Arnott, C. Effect of Canagliflozin on total hospitalization for heart failure events in patients with Type 2 diabetes and chronic kidney disease. Presented at: ADA 2020 Annual Meeting, OR, USA. 2020, June 12–16.
[81]	Cannon, C.P.; Perkovic, V.; Agarwal, R.; Baldassarre, J.; Bakris, G.; Charytan, D.M.; de Zeeuw, D.; Edwards, R.; Greene, T.; Heerspink, H.J.L.; Jardine, M.J.; Levin, A.; Li, J.W.; Neal, B.; Pollock, C.; Wheeler, D.C.; Zhang, H.; Zinman, B.; Mahaffey, K.W. Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c < 7%: results from the CREDENCE trial. Circulation. 2020, 141, 407–410.
[82]	Bays, H.E.; Weinstein, R.; Law, G.; Canovatchel, W. Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus. Obesity. 2014, 22, 1042–1049.
[83]	Mohamed Abouelkheir, A.E.T. SGLT2 Inhibitors and Cancer: is Immunity the Missing Link? J of Pharmacol & Clin Res. 2019, 6, 4.
[84]	Lin, H.W.; Tseng, C.H. A review on the relationship between SGLT2 inhibitors and cancer. Int. J. Endocrinol. 2014, 2014, 719578.
[85]	Scafoglio, C.; Hirayama, B.A.; Kepe, V.; Liu, J.; Ghezzi, C.; Satyamurthy, N.; Moatamed, N.A.; Huang, J.T.; Koepsell, H.; Barrio, J.R.; Wright, E.M. Functional expression of sodium-glucose transporters in cancer. PNAS. 2015, 112, E4111–E4119.
[86]	Shiba, K.; Tsuchiya, K.; Komiya, C.; Miyachi, Y.; Mori, K.; Shimazu, N.; Yamaguchi, S.; Ogasawara, N.; Katoh, M.; Itoh, M.; Suganami, T.; Ogawa, Y. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 2018, 8, 2362.
[87]	Kaji, K.; Nishimura, N.; Seki, K.; Sato, S.; Saikawa, S.; Nakanishi, K.; Furukawa, M.; Kawaratani, H.; Kitade, M.; Moriya, K.; Namisaki, T.; Yoshiji, H. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int. J. Cancer. 2018, 142, 1712–1722.
[88]	Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 2017, 377, 644–657.
[89]	Udell, J.A.; Yuan, Z.; Rush, T.; Sicignano, N.M.; Galitz, M.; Rosenthal, N. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: results from the EASEL population-based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation. 2018, 137, 1450–1459.
[90]	Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 2017, 377, 644–657.
[91]	Watts, N.B.; Bilezikian, J.P.; Usiskin, K.; Edwards, R.; Desai, M.; Law, G.; Meininger, G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2016, 101, 157–166.
[92]	Blau, J.E.; Bauman, V.; Conway, E.M.; Piaggi, P.; Walter, M.F.; Wright, E.C.; Bernstein, S.; Courville, A.B.; Collins, M.T.; Rother, K.I.; Taylor, S.I. Canagliflozin triggers the FGF23/1, 25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight. 2018, 3.
[93]	Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl. J. Med. 2019, 380, 2295–2306.
[94]	Ryan, P.B.; Buse, J.B.; Schuemie, M.J.; DeFalco, F.; Yuan, Z.; Stang, P.E.; Berlin, J.A.; Rosenthal, N. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes. Metab. 2018, 20, 2585–2597.
[95]	Yuan, Z.; DeFalco, F.J.; Ryan, P.B.; Schuemie, M.J.; Stang, P.E.; Berlin, J.A.; Desai, M.; Rosenthal, N. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes. Metab. 2018, 20, 582–589.
[96]	Adimadhyam, S.; Lee, T.A.; Calip, G.S.; Smith Marsh, D.E.; Layden, B.T.; Schumock, G.T. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: a propensity-matched cohort study. Diabetes Obes. Metab. 2018, 20, 2792–2799.
[97]	Ruanpeng, D.; Ungprasert, P.; Sangtian, J.; Harindhanavudhi, T. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Metab. Res. Rev. 2017, 33, e2903.
[98]	Erythropoulou-Kaltsidou, A.; Polychronopoulos, G.; Tziomalos, K. Sodium-glucose co-transporter 2 inhibitors and fracture risk. Diabetes Ther. 2020, 11, 7–14.
[99]	Fralick, M.; Kim, S.C.; Schneeweiss, S.; Kim, D.; Redelmeier, D.A.; Patorno, E. Fracture risk after initiation of use of canagliflozin: a cohort study. Ann. Intern. Med. 2019, 170, 155–163.
[100]	Miyashita, S.; Kuno, T.; Takagi, H.; Sugiyama, T.; Ando, T.; Valentin, N.; Shimada, Y.J.; Kodaira, M.; Numasawa, Y.; Kanei, Y.; Bangalore, S. Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of five randomized controlled trials. Diabetes Res. Clin. Pract. 2020, 163, 108136.
[101]	Arnott, C.; Huang, Y.L.; Neuen, B.L.; di Tanna, G.L.; Cannon, C.P.; Oh, R.; Edwards, R.; Kavalam, M.; Rosenthal, N.; Perkovic, V.; Jardine, M.J.; Mahaffey, K.; Neal, B. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial. Diabetes Obes. Metab. 2020, 22, 1753–1766.
[102]	Chowdhary, M.; Kabbani, A.A.; Chhabra, A. Canagliflozin-induced pancreatitis: a rare side effect of a new drug. Ther. Clin. Risk Manag. 2015, 11, 991–994.
[103]	Verma, R. Canagliflozin-associated acute pancreatitis. Am. J. Ther. 2016, 23, e972–e973.